<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> is a risk factor for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the present study was to identify genetic variants that confer susceptibility to atherothrombotic <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> among individuals with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in order to allow prediction of genetic risk for this condition </plain></SENT>
<SENT sid="2" pm="."><plain>The study population comprised 1284 unrelated Japanese individuals with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, including 313 subjects with atherothrombotic <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and 971 controls </plain></SENT>
<SENT sid="3" pm="."><plain>The genotypes for 296 polymorphisms of 202 candidate genes were determined with a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology </plain></SENT>
<SENT sid="4" pm="."><plain>The Chi-square test, multivariable logistic regression analysis with adjustment for age, sex, body mass index, and the prevalence of <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo>, and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, as well as a stepwise forward selection procedure revealed that the 2445G--&gt;A (Ala54Thr) polymorphism (rs1799883) of FABP2, the -108/3G--&gt;4G polymorphism of IPF1 (S82168), the A--&gt;G (Thr94Ala) polymorphism (rs2241883) of FABP1, the G--&gt;A (Asp2213Asn) polymorphism (rs529038) of ROS1, the -11377C--&gt;G polymorphism (rs266729) of ADIPOQ, the 162A--&gt;C polymorphism (rs4769055) of ALOX5AP, the -786T--&gt;C polymorphism (rs2070744) of NOS3, and the 3279C--&gt;T polymorphism (rs7291467) of LGALS2 were associated (P&lt;0.05) with the prevalence of atherothrombotic <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Among these polymorphisms, the 2445G--&gt;A (Ala54Thr) polymorphism of FABP2 was most significantly associated with this condition </plain></SENT>
<SENT sid="6" pm="."><plain>Our results suggest that FABP2, IPF1, FABP1, ROS1, ADIPOQ, ALOX5AP, NOS3, and LGALS2 are susceptibility loci for atherothrombotic <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> among Japanese individuals with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Genotypes for these polymorphisms, especially for the 2445G--&gt;A (Ala54Thr) polymorphism of FABP2, may prove informative for the prediction of genetic risk for atherothrombotic <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> among such individuals </plain></SENT>
</text></document>